CNPR, NAPSR Exam
____ new medicines are developed for HIV/AIDS - ANS - 185
\_____ new medicines are in development for diabetes - ANS - 281
\______ medicines are in development for cancer - ANS - 3070
\______ new treatments have been approved for Hep C - ANS - 2
\_______ new treatments for Alzheimer's disease are in development - ANS - 125
\"Pull through" refers to: - ANS - generating demand for your company's product
\"Pull through" refers to: - ANS - generating demand for your company's product
\(T/F) Pharmaceutical development is a high risk undertaking that often proves disappointing. -
ANS - True
\1st right of drug administration - ANS - right patient
\2nd right of drug administration - ANS - Right medication
\3,070 new meds are in development for cancer. - ANS - True
\3rd right of drug administration - ANS - right dose
\4th right of drug administration - ANS - right route of administration
\5 rights of drug administration - ANS - Right dose, right patient, right medication, right route of
administration, right time of delivery
\5th right of drug administration - ANS - right time of delivery
\6 stages of brand strategy - ANS - Brand positioning, brand personality, brand values, unique
values of the brand that support the values, how the brand appears to its audience, internal
commitment
\6 stages of brand strategy - ANS - Brand positioning, brand personality, brand values, unique
values of the brand that support the values, how the brand appears to its audience, internal
commitment
\A _____ is an inactive medication with no treatment value, used in experimental studies. - ANS
- placebo
\A _____ is an inactive medication with no treatment value, used in experimental studies. - ANS
- placebo
\A formulary is a list of prescription drugs approved by insurance coverage. - ANS - true
\A formulary is a list of prescription drugs approved by insurance coverage. - ANS - true
\A generic drug is ______ to the originator brand-name drug in dosage, strength, safety, and
quality. - ANS - bioequivalent
\A generic drug is ______ to the originator brand-name drug in dosage, strength, safety, and
quality. - ANS - bioevuivalent
\A low supply of oxygen due to low blood flow is - ANS - ischemia
\A low supply of oxygen due to low blood flow is: - ANS - ischemia
\A OBR - ANS - products for which there are no known or suspected bioequivalence problems
\A patent owner has the right to exclude others from making, using, selling or importing into the
US the ____ it describes. - ANS - invention
\A patent owner has the right to exclude others from making, using, selling or importing into the
US the ____ it describes. - ANS - invention
,\A sample closet or cabinet is essentially similar to a grocery store shelf. The more visibility you
can give your drug, the more likely it will be used. - ANS - True
\A site in the body which generally resides on a cell surface or within the cytoplasm. When
stimulated or occupied, a biological change/activity takes place: - ANS - receptor
\A site in the body which generally resides on a cell surface or within the cytoplasm. When
stimulated or occupied, a biological change/activity takes place: - ANS - receptor
\A substance that enhances the action of a drug or antigen: - ANS - adjuvant
\A substance that enhances the action of a drug or antigen: - ANS - adjuvant
\A term used to refer to drugs that are non-biological (that is, chemical) in nature: - ANS - small
molecule
\A type of blood cell that helps the body fight infection and disease: - ANS - white blood cell
\A type of blood cell that helps the body fight infection and disease: - ANS - white blood cell
\AA OBR - ANS - products in conventional dosage forms with no bioequivalence problems
\Absorption - ANS - How the drug passes from its side of administration into the bloodstream
\Absorption methods - ANS - Oral, Buccal, sublingual, rectal, subcutaneous, intramuscular,
transdermal, topical, inhalation, intravenous
\Absorption methods - ANS - Oral, Buccal, sublingual, rectal, subcutaneous, intramuscular,
transdermal, topical, inhalation, intravenous
\According to the text, depression is a disease that attacks the: - ANS - central nervous system
\According to the text, depression is a disease that attacks the: - ANS - central nervous system
\According to the text, there are ___ classes of therapeutic drugs - ANS - US federal govt
\According to the text, there are ___ classes of therapeutic drugs. - ANS - US federal govt
\According to the text, which of the following is considered "going to the next level?" - ANS -
staying focused
\According to the text, which of the following is considered "going to the next level?" - ANS -
staying focused
\Acute medications, such as antibiotics, are used to address short-term illnesses or symptoms. -
ANS - true
\Acute medications, such as antibiotics, are used to address short-term illnesses or symptoms. -
ANS - true
\Adendovirus - ANS - This vector has a large capacity for foreign genes.
\Adendovirus - ANS - This vector has a large capacity for foreign genes.
\Adjuvants - ANS - a substance that enhances the actions of drug antigen; second form of
treatment in addition to primary care examples: chemo in addition to surgery
\Adjuvants - ANS - pg 110
\ADME - ANS - testing that measures the rate at which the body absorbs the drug, distributes it
to the organs necessary to produce the desired effect, metabolizes it into waste material, and
then excretes it from the body
\AEs - ANS - adverse events
\agonist - ANS - drugs that activate receptors
\Almost 98% of employed Americans are now covered by a HMO, a preferred provider
organization, or a point-of-service plan. - ANS - false
\Almost 98% of employed Americans are now covered by a HMO, a preferred provider
organization, or a point-of-service plan. - ANS - false
, \Almost 98% of employed Americans are now covered by a HMO, a preferred provider
organization, or a point-of-service plan. - ANS - false
\Almost 98% of employed Americans are now covered by a HMO, a preferred provider
organization, or a point-of-service plan. - ANS - false
\alteration - ANS - one drug may alter how the body absorbs, distributes, metabolizes, or
excretes another drug
\AMA - ANS - provides ethical guidelines to physicians about appropriate interactions with
pharmaceutical companies
\AMA - ANS - provides ethical guidelines to physicians about appropriate interactions with
pharmaceutical companies
\AMA Gift guidelines - ANS - Pg 165
\AMA gift Guidelines - ANS - pg 231
\Among the biotechnology medications under development, about _____ target cancer. - ANS -
50%
\Among the biotechnology medications under development, about _____ target cancer. - ANS -
50%
\AN OBR - ANS - solutions and powders
\Anatomy - ANS - The study of basic structures of the body
\anatomy - ANS - the study of the basic structures of the body
\ANDA - ANS - abbreviated new drug application
\Another name for biologic compound is: - ANS - large molecule
\Another name for biologic compound is: - ANS - large molecule
\antagonist - ANS - drugs that block receptors
\Any gifts accepted by physicians individually should entail a benefit to the patient and not be of
substantial value - ANS - true
\Any gifts accepted by physicians individually should entail a benefit to the patient and not be of
substantial value - ANS - True
\AO OBR - ANS - Injectable oil solutions
\AP - ANS - injectable aqueous solutions
\API - ANS - active pharmaceutical ingredient two basic categories: chemical and biological
\approvable letter - ANS - letters sent by the FDA to the applicant indicating whether the new
drug application meets necessary requirements
\Areas of drug elimination and excretion - ANS - Lungs, breast milk, sweat tears urine feces,
bile, saliva, and exhaled air
\ASAP order - ANS - within 30 minutes of written order
\Asymptomatic - ANS - Without signs or symptoms
\asymptomatic - ANS - without signs or symptoms of disease
\AT - ANS - topical products
\AUC - ANS - area under the curve, represents the extent of drug absorption or the quantity of a
drug that appears in the bloodstream following oral administration
\AUC - ANS - represents the extent of the drug absorption or the quantity of the drug that
appears in the bloodstream following oral administration
____ new medicines are developed for HIV/AIDS - ANS - 185
\_____ new medicines are in development for diabetes - ANS - 281
\______ medicines are in development for cancer - ANS - 3070
\______ new treatments have been approved for Hep C - ANS - 2
\_______ new treatments for Alzheimer's disease are in development - ANS - 125
\"Pull through" refers to: - ANS - generating demand for your company's product
\"Pull through" refers to: - ANS - generating demand for your company's product
\(T/F) Pharmaceutical development is a high risk undertaking that often proves disappointing. -
ANS - True
\1st right of drug administration - ANS - right patient
\2nd right of drug administration - ANS - Right medication
\3,070 new meds are in development for cancer. - ANS - True
\3rd right of drug administration - ANS - right dose
\4th right of drug administration - ANS - right route of administration
\5 rights of drug administration - ANS - Right dose, right patient, right medication, right route of
administration, right time of delivery
\5th right of drug administration - ANS - right time of delivery
\6 stages of brand strategy - ANS - Brand positioning, brand personality, brand values, unique
values of the brand that support the values, how the brand appears to its audience, internal
commitment
\6 stages of brand strategy - ANS - Brand positioning, brand personality, brand values, unique
values of the brand that support the values, how the brand appears to its audience, internal
commitment
\A _____ is an inactive medication with no treatment value, used in experimental studies. - ANS
- placebo
\A _____ is an inactive medication with no treatment value, used in experimental studies. - ANS
- placebo
\A formulary is a list of prescription drugs approved by insurance coverage. - ANS - true
\A formulary is a list of prescription drugs approved by insurance coverage. - ANS - true
\A generic drug is ______ to the originator brand-name drug in dosage, strength, safety, and
quality. - ANS - bioequivalent
\A generic drug is ______ to the originator brand-name drug in dosage, strength, safety, and
quality. - ANS - bioevuivalent
\A low supply of oxygen due to low blood flow is - ANS - ischemia
\A low supply of oxygen due to low blood flow is: - ANS - ischemia
\A OBR - ANS - products for which there are no known or suspected bioequivalence problems
\A patent owner has the right to exclude others from making, using, selling or importing into the
US the ____ it describes. - ANS - invention
\A patent owner has the right to exclude others from making, using, selling or importing into the
US the ____ it describes. - ANS - invention
,\A sample closet or cabinet is essentially similar to a grocery store shelf. The more visibility you
can give your drug, the more likely it will be used. - ANS - True
\A site in the body which generally resides on a cell surface or within the cytoplasm. When
stimulated or occupied, a biological change/activity takes place: - ANS - receptor
\A site in the body which generally resides on a cell surface or within the cytoplasm. When
stimulated or occupied, a biological change/activity takes place: - ANS - receptor
\A substance that enhances the action of a drug or antigen: - ANS - adjuvant
\A substance that enhances the action of a drug or antigen: - ANS - adjuvant
\A term used to refer to drugs that are non-biological (that is, chemical) in nature: - ANS - small
molecule
\A type of blood cell that helps the body fight infection and disease: - ANS - white blood cell
\A type of blood cell that helps the body fight infection and disease: - ANS - white blood cell
\AA OBR - ANS - products in conventional dosage forms with no bioequivalence problems
\Absorption - ANS - How the drug passes from its side of administration into the bloodstream
\Absorption methods - ANS - Oral, Buccal, sublingual, rectal, subcutaneous, intramuscular,
transdermal, topical, inhalation, intravenous
\Absorption methods - ANS - Oral, Buccal, sublingual, rectal, subcutaneous, intramuscular,
transdermal, topical, inhalation, intravenous
\According to the text, depression is a disease that attacks the: - ANS - central nervous system
\According to the text, depression is a disease that attacks the: - ANS - central nervous system
\According to the text, there are ___ classes of therapeutic drugs - ANS - US federal govt
\According to the text, there are ___ classes of therapeutic drugs. - ANS - US federal govt
\According to the text, which of the following is considered "going to the next level?" - ANS -
staying focused
\According to the text, which of the following is considered "going to the next level?" - ANS -
staying focused
\Acute medications, such as antibiotics, are used to address short-term illnesses or symptoms. -
ANS - true
\Acute medications, such as antibiotics, are used to address short-term illnesses or symptoms. -
ANS - true
\Adendovirus - ANS - This vector has a large capacity for foreign genes.
\Adendovirus - ANS - This vector has a large capacity for foreign genes.
\Adjuvants - ANS - a substance that enhances the actions of drug antigen; second form of
treatment in addition to primary care examples: chemo in addition to surgery
\Adjuvants - ANS - pg 110
\ADME - ANS - testing that measures the rate at which the body absorbs the drug, distributes it
to the organs necessary to produce the desired effect, metabolizes it into waste material, and
then excretes it from the body
\AEs - ANS - adverse events
\agonist - ANS - drugs that activate receptors
\Almost 98% of employed Americans are now covered by a HMO, a preferred provider
organization, or a point-of-service plan. - ANS - false
\Almost 98% of employed Americans are now covered by a HMO, a preferred provider
organization, or a point-of-service plan. - ANS - false
, \Almost 98% of employed Americans are now covered by a HMO, a preferred provider
organization, or a point-of-service plan. - ANS - false
\Almost 98% of employed Americans are now covered by a HMO, a preferred provider
organization, or a point-of-service plan. - ANS - false
\alteration - ANS - one drug may alter how the body absorbs, distributes, metabolizes, or
excretes another drug
\AMA - ANS - provides ethical guidelines to physicians about appropriate interactions with
pharmaceutical companies
\AMA - ANS - provides ethical guidelines to physicians about appropriate interactions with
pharmaceutical companies
\AMA Gift guidelines - ANS - Pg 165
\AMA gift Guidelines - ANS - pg 231
\Among the biotechnology medications under development, about _____ target cancer. - ANS -
50%
\Among the biotechnology medications under development, about _____ target cancer. - ANS -
50%
\AN OBR - ANS - solutions and powders
\Anatomy - ANS - The study of basic structures of the body
\anatomy - ANS - the study of the basic structures of the body
\ANDA - ANS - abbreviated new drug application
\Another name for biologic compound is: - ANS - large molecule
\Another name for biologic compound is: - ANS - large molecule
\antagonist - ANS - drugs that block receptors
\Any gifts accepted by physicians individually should entail a benefit to the patient and not be of
substantial value - ANS - true
\Any gifts accepted by physicians individually should entail a benefit to the patient and not be of
substantial value - ANS - True
\AO OBR - ANS - Injectable oil solutions
\AP - ANS - injectable aqueous solutions
\API - ANS - active pharmaceutical ingredient two basic categories: chemical and biological
\approvable letter - ANS - letters sent by the FDA to the applicant indicating whether the new
drug application meets necessary requirements
\Areas of drug elimination and excretion - ANS - Lungs, breast milk, sweat tears urine feces,
bile, saliva, and exhaled air
\ASAP order - ANS - within 30 minutes of written order
\Asymptomatic - ANS - Without signs or symptoms
\asymptomatic - ANS - without signs or symptoms of disease
\AT - ANS - topical products
\AUC - ANS - area under the curve, represents the extent of drug absorption or the quantity of a
drug that appears in the bloodstream following oral administration
\AUC - ANS - represents the extent of the drug absorption or the quantity of the drug that
appears in the bloodstream following oral administration
